HB 56 Allows pharmaceutical companies to rebate portions of copayments to multiple sclerosis patients without violating anti-kickback and anti-rebate laws

     Handler: Dolan

Current Bill Summary

- Prepared by Senate Research -


HCS/HB 56 - This act provides that the anti-kickback, anti-rebating and other prohibited financial incentive provisions of Section 191.905 shall not apply to pharmaceutical programs that rebate a portion of health insurance copayments and coinsurance to multiple sclerosis patients or others suffering from chronic conditions who have been prescribed medicines for which there are no generic equivalents.

STEPHEN WITTE


Go to Main Bill Page  |  Return to Summary List  |  Return to Senate Home Page